nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acinetobacter/stenotrophomonas
|
|
|
1999 |
5 |
S3 |
p. 367-371 5 p. |
artikel |
2 |
Animal models
|
|
|
1999 |
5 |
S3 |
p. 339-342 4 p. |
artikel |
3 |
Bacteremia/endocarditis
|
|
|
1999 |
5 |
S3 |
p. 371-378 8 p. |
artikel |
4 |
Beta-lactamase/ESBL
|
|
|
1999 |
5 |
S3 |
p. 106-112 7 p. |
artikel |
5 |
Carbapenems in serious infections: maximizing the power, minimizing resistance
|
|
|
1999 |
5 |
S3 |
p. 12-14 3 p. |
artikel |
6 |
Challenges in the treatment of febrile neutropenia
|
|
|
1999 |
5 |
S3 |
p. 47-48 2 p. |
artikel |
7 |
Changing treatment perceptions in community-acquired lower respiratory tract infections
|
|
|
1999 |
5 |
S3 |
p. 4-5 2 p. |
artikel |
8 |
Chlamydia pneumoniae—a pathogen involved in many diseases
|
|
|
1999 |
5 |
S3 |
p. 11- 1 p. |
artikel |
9 |
Chronic hepatitis: new approaches in diagnosis and treatment
|
|
|
1999 |
5 |
S3 |
p. 41-42 2 p. |
artikel |
10 |
Clinical impact of new diagnostic methods in microbiology
|
|
|
1999 |
5 |
S3 |
p. 18-19 2 p. |
artikel |
11 |
Clinical implications of antibiotics resistance in developing countries
|
|
|
1999 |
5 |
S3 |
p. 27- 1 p. |
artikel |
12 |
Clinical microbiology: a pivotal interface in patient and health care management
|
|
|
1999 |
5 |
S3 |
p. 7-8 2 p. |
artikel |
13 |
Community acquired pneumonia
|
|
|
1999 |
5 |
S3 |
p. 151-157 7 p. |
artikel |
14 |
Community-acquired pneumonia (CAP) in the next century
|
|
|
1999 |
5 |
S3 |
p. 29- 1 p. |
artikel |
15 |
Current aspects in anaerobic infections
|
|
|
1999 |
5 |
S3 |
p. 36-37 2 p. |
artikel |
16 |
Disinfection and surgical infections
|
|
|
1999 |
5 |
S3 |
p. 387-389 3 p. |
artikel |
17 |
Emerging pediatric infectious diseases
|
|
|
1999 |
5 |
S3 |
p. 38-39 2 p. |
artikel |
18 |
Endocarditis and Sepsis
|
|
|
1999 |
5 |
S3 |
p. 56-58 3 p. |
artikel |
19 |
Enteric pathogens
|
|
|
1999 |
5 |
S3 |
p. 265-272 8 p. |
artikel |
20 |
Epidemiology/surveillance and outbreaks
|
|
|
1999 |
5 |
S3 |
p. 63-64 2 p. |
artikel |
21 |
Eradication of infectious diseases—past and future
|
|
|
1999 |
5 |
S3 |
p. 34-35 2 p. |
artikel |
22 |
Exotoxins
|
|
|
1999 |
5 |
S3 |
p. 24-26 3 p. |
artikel |
23 |
Fluoroquinolones I
|
|
|
1999 |
5 |
S3 |
p. 138-148 11 p. |
artikel |
24 |
Fluoroquinolones II
|
|
|
1999 |
5 |
S3 |
p. 296-304 9 p. |
artikel |
25 |
Fungal diseases: diagnosis, virulence factors, antifungal agents
|
|
|
1999 |
5 |
S3 |
p. 64-66 3 p. |
artikel |
26 |
Fungal infections I
|
|
|
1999 |
5 |
S3 |
p. 278-286 9 p. |
artikel |
27 |
Fungal infections II
|
|
|
1999 |
5 |
S3 |
p. 396-404 9 p. |
artikel |
28 |
Genome analysis and infectious diseases
|
|
|
1999 |
5 |
S3 |
p. 10- 1 p. |
artikel |
29 |
Glycopeptide resistance
|
|
|
1999 |
5 |
S3 |
p. 31- 1 p. |
artikel |
30 |
Hantavirus—pathogenesis diagnosis, clinical approach
|
|
|
1999 |
5 |
S3 |
p. 45-46 2 p. |
artikel |
31 |
Health care issues/public health
|
|
|
1999 |
5 |
S3 |
p. 85-91 7 p. |
artikel |
32 |
Helicobacter pylori
|
|
|
1999 |
5 |
S3 |
p. 42- 1 p. |
artikel |
33 |
Helicobacter pylori
|
|
|
1999 |
5 |
S3 |
p. 258-265 8 p. |
artikel |
34 |
Hepatitis
|
|
|
1999 |
5 |
S3 |
p. 218-227 10 p. |
artikel |
35 |
HIV/AIDS
|
|
|
1999 |
5 |
S3 |
p. 53-56 4 p. |
artikel |
36 |
HIV-epidemiology, opportunistic infections I
|
|
|
1999 |
5 |
S3 |
p. 157-163 7 p. |
artikel |
37 |
HIV-epidemiology, opportunistic infections II
|
|
|
1999 |
5 |
S3 |
p. 342-348 7 p. |
artikel |
38 |
HIV-virology and treatment
|
|
|
1999 |
5 |
S3 |
p. 227-235 9 p. |
artikel |
39 |
Hospital-acquired bloodstream infections
|
|
|
1999 |
5 |
S3 |
p. 32- 1 p. |
artikel |
40 |
Immune reconstitution in HIV disease
|
|
|
1999 |
5 |
S3 |
p. 15- 1 p. |
artikel |
41 |
Immunocompromised host
|
|
|
1999 |
5 |
S3 |
p. 353-359 7 p. |
artikel |
42 |
Immunology, host defences, vaccination I
|
|
|
1999 |
5 |
S3 |
p. 124-130 7 p. |
artikel |
43 |
Immunology, host defences, vaccination II
|
|
|
1999 |
5 |
S3 |
p. 242-248 7 p. |
artikel |
44 |
Immunology, host defences, vaccination III
|
|
|
1999 |
5 |
S3 |
p. 326-332 7 p. |
artikel |
45 |
Immunotherapy in infectious disease—novel treatment concepts
|
|
|
1999 |
5 |
S3 |
p. 30- 1 p. |
artikel |
46 |
Increasing resistance in Gram-positive pathogens
|
|
|
1999 |
5 |
S3 |
p. 3-4 2 p. |
artikel |
47 |
Infections and cytokines
|
|
|
1999 |
5 |
S3 |
p. 20-21 2 p. |
artikel |
48 |
Infections by Gram-positive bacteria
|
|
|
1999 |
5 |
S3 |
p. 323-326 4 p. |
artikel |
49 |
Infections by non-tuberculous mycobacteria
|
|
|
1999 |
5 |
S3 |
p. 50-51 2 p. |
artikel |
50 |
Infections in the immunocompromised non-neutropenic patient
|
|
|
1999 |
5 |
S3 |
p. 49-50 2 p. |
artikel |
51 |
Infectious disease in the 21st century
|
|
|
1999 |
5 |
S3 |
p. 46- 1 p. |
artikel |
52 |
Infectious disease problems in Central and Eastern Europe
|
|
|
1999 |
5 |
S3 |
p. 16-18 3 p. |
artikel |
53 |
Inflammatory host responses
|
|
|
1999 |
5 |
S3 |
p. 66-69 4 p. |
artikel |
54 |
Intensive care unit
|
|
|
1999 |
5 |
S3 |
p. 360-364 5 p. |
artikel |
55 |
Intestinal protozoa and echinococcosis
|
|
|
1999 |
5 |
S3 |
p. 9-10 2 p. |
artikel |
56 |
Laboratory diagnosis: Automation I
|
|
|
1999 |
5 |
S3 |
p. 91-95 5 p. |
artikel |
57 |
Laboratory diagnosis: Automation II
|
|
|
1999 |
5 |
S3 |
p. 304-308 5 p. |
artikel |
58 |
Lower respiratory tract infection
|
|
|
1999 |
5 |
S3 |
p. 80-83 4 p. |
artikel |
59 |
Lyme disease
|
|
|
1999 |
5 |
S3 |
p. 255-258 4 p. |
artikel |
60 |
Meningitis
|
|
|
1999 |
5 |
S3 |
p. 248-252 5 p. |
artikel |
61 |
Methicillin-resistant staphylococci
|
|
|
1999 |
5 |
S3 |
p. 113-120 8 p. |
artikel |
62 |
Methicillin-resistant Staphylococcus aureus (MRSA)/Vancomycin-resistant enterococci (VRE)
|
|
|
1999 |
5 |
S3 |
p. 72-75 4 p. |
artikel |
63 |
Miscellaneous
|
|
|
1999 |
5 |
S3 |
p. 404-410 7 p. |
artikel |
64 |
Molecular diagnostic methods
|
|
|
1999 |
5 |
S3 |
p. 69-72 4 p. |
artikel |
65 |
Molecular methods for the diagnosis of infectious diseases
|
|
|
1999 |
5 |
S3 |
p. 21-22 2 p. |
artikel |
66 |
Molecular methods in the diagnostic laboratory: when to start and where to stop
|
|
|
1999 |
5 |
S3 |
p. 40-41 2 p. |
artikel |
67 |
Molecular typing
|
|
|
1999 |
5 |
S3 |
p. 193-199 7 p. |
artikel |
68 |
Mycobacteria
|
|
|
1999 |
5 |
S3 |
p. 61-63 3 p. |
artikel |
69 |
Mycobacterial diseases
|
|
|
1999 |
5 |
S3 |
p. 26-27 2 p. |
artikel |
70 |
Mycobacteria-Tbc I
|
|
|
1999 |
5 |
S3 |
p. 95-101 7 p. |
artikel |
71 |
Mycobacteria-Tbc II
|
|
|
1999 |
5 |
S3 |
p. 199-205 7 p. |
artikel |
72 |
Neonatal infections
|
|
|
1999 |
5 |
S3 |
p. 168-171 4 p. |
artikel |
73 |
New advances in the diagnosis and treatment of fungal infections
|
|
|
1999 |
5 |
S3 |
p. 5-7 3 p. |
artikel |
74 |
New aspects of cystic fibrosis, lung infection and inflammation
|
|
|
1999 |
5 |
S3 |
p. 48- 1 p. |
artikel |
75 |
New developments in treatment of respiratory tract infections
|
|
|
1999 |
5 |
S3 |
p. 39-40 2 p. |
artikel |
76 |
New drugs
|
|
|
1999 |
5 |
S3 |
p. 130-138 9 p. |
artikel |
77 |
New insights into sepsis and septic shock
|
|
|
1999 |
5 |
S3 |
p. 3- 1 p. |
artikel |
78 |
New insights into the pathogenesis and therapy of sepsis
|
|
|
1999 |
5 |
S3 |
p. 14-15 2 p. |
artikel |
79 |
New opportunities to improve outcomes in community RTIs
|
|
|
1999 |
5 |
S3 |
p. 44-45 2 p. |
artikel |
80 |
Next generation quinolones for a new therapeutic millennium
|
|
|
1999 |
5 |
S3 |
p. 23-24 2 p. |
artikel |
81 |
Nosocomial pneumonia
|
|
|
1999 |
5 |
S3 |
p. 364-367 4 p. |
artikel |
82 |
Outbreaks
|
|
|
1999 |
5 |
S3 |
p. 389-393 5 p. |
artikel |
83 |
Parasitic diseases
|
|
|
1999 |
5 |
S3 |
p. 171-175 5 p. |
artikel |
84 |
Pathogenesis
|
|
|
1999 |
5 |
S3 |
p. 332-339 8 p. |
artikel |
85 |
Pathogenesis and prevention of polymer-associated staphylococcal infections
|
|
|
1999 |
5 |
S3 |
p. 18- 1 p. |
artikel |
86 |
Pediatric infections including vaccination I
|
|
|
1999 |
5 |
S3 |
p. 163-168 6 p. |
artikel |
87 |
Pediatric infections including vaccination II
|
|
|
1999 |
5 |
S3 |
p. 348-353 6 p. |
artikel |
88 |
Pharmacoeconomics in infectious diseases
|
|
|
1999 |
5 |
S3 |
p. 50- 1 p. |
artikel |
89 |
Pharmacokinetics/pharmacodynamics
|
|
|
1999 |
5 |
S3 |
p. 289-295 7 p. |
artikel |
90 |
Prevention of infections in immunocompromised patients
|
|
|
1999 |
5 |
S3 |
p. 22-23 2 p. |
artikel |
91 |
Progress in meningitis
|
|
|
1999 |
5 |
S3 |
p. 22- 1 p. |
artikel |
92 |
Progress in vaccination
|
|
|
1999 |
5 |
S3 |
p. 43-44 2 p. |
artikel |
93 |
Quality aspects in clinical microbiology
|
|
|
1999 |
5 |
S3 |
p. 8-9 2 p. |
artikel |
94 |
Rare diseases
|
|
|
1999 |
5 |
S3 |
p. 180-185 6 p. |
artikel |
95 |
Recent developments in cardiovascular infections
|
|
|
1999 |
5 |
S3 |
p. 35-36 2 p. |
artikel |
96 |
Resistance—epidemiology and mechanism
|
|
|
1999 |
5 |
S3 |
p. 75-77 3 p. |
artikel |
97 |
Resistance/epidemiology I
|
|
|
1999 |
5 |
S3 |
p. 236-242 7 p. |
artikel |
98 |
Resistance/epidemiology II
|
|
|
1999 |
5 |
S3 |
p. 309-315 7 p. |
artikel |
99 |
Resistance grampositive bacteria
|
|
|
1999 |
5 |
S3 |
p. 315-323 9 p. |
artikel |
100 |
Resistance mechanisms
|
|
|
1999 |
5 |
S3 |
p. 101-106 6 p. |
artikel |
101 |
Resistant bacteria—their evolution and pharmacodynamic response to antimicrobials
|
|
|
1999 |
5 |
S3 |
p. 22- 1 p. |
artikel |
102 |
Respiratory infections: strategies for a resistance environment
|
|
|
1999 |
5 |
S3 |
p. 19-20 2 p. |
artikel |
103 |
Respiratory tract infections
|
|
|
1999 |
5 |
S3 |
p. 272-278 7 p. |
artikel |
104 |
Serodiagnosis
|
|
|
1999 |
5 |
S3 |
p. 308-309 2 p. |
artikel |
105 |
Severe infections/osteomyelitis
|
|
|
1999 |
5 |
S3 |
p. 378-380 3 p. |
artikel |
106 |
Sexually-transmitted diseases (STD) and chlamydial diagnostics
|
|
|
1999 |
5 |
S3 |
p. 185-193 9 p. |
artikel |
107 |
Short course antibiotic therapy with macrolides
|
|
|
1999 |
5 |
S3 |
p. 27-28 2 p. |
artikel |
108 |
Solid organ transplants
|
|
|
1999 |
5 |
S3 |
p. 286-289 4 p. |
artikel |
109 |
Surgical infections and burns
|
|
|
1999 |
5 |
S3 |
p. 384-387 4 p. |
artikel |
110 |
Surveillance
|
|
|
1999 |
5 |
S3 |
p. 393-396 4 p. |
artikel |
111 |
Surveillance of nosocomial infections in Europe: which methodologies?
|
|
|
1999 |
5 |
S3 |
p. 12- 1 p. |
artikel |
112 |
Tb Meningitis/extrapulmonary Tb
|
|
|
1999 |
5 |
S3 |
p. 252-255 4 p. |
artikel |
113 |
The role of chemokines and chemokine receptors in the pathogenicity of HIV
|
|
|
1999 |
5 |
S3 |
p. 3- 1 p. |
artikel |
114 |
Thinking like bacteria—the modern approach to overcome resistance in Gram-negative bacteria
|
|
|
1999 |
5 |
S3 |
p. 15-16 2 p. |
artikel |
115 |
Tolerability/toxicity
|
|
|
1999 |
5 |
S3 |
p. 148-151 4 p. |
artikel |
116 |
Towards an integrated molocular epidemiology of infectious diseases: epidemicity, virulence and host susceptibility markers
|
|
|
1999 |
5 |
S3 |
p. 32-33 2 p. |
artikel |
117 |
Toxicity of antimicrobial agents: relevance of preclinical data for the clinician
|
|
|
1999 |
5 |
S3 |
p. 16- 1 p. |
artikel |
118 |
Toxoplasmosis and its control
|
|
|
1999 |
5 |
S3 |
p. 43- 1 p. |
artikel |
119 |
Tropical and parasitic diseases
|
|
|
1999 |
5 |
S3 |
p. 58-60 3 p. |
artikel |
120 |
Urinary tract infections
|
|
|
1999 |
5 |
S3 |
p. 175-180 6 p. |
artikel |
121 |
Use of indicators for good infection control practice
|
|
|
1999 |
5 |
S3 |
p. 37-38 2 p. |
artikel |
122 |
Vancomycin-resistant enterococci
|
|
|
1999 |
5 |
S3 |
p. 120-124 5 p. |
artikel |
123 |
Vascular infections (Bartonella/Chlamydia)
|
|
|
1999 |
5 |
S3 |
p. 380-383 4 p. |
artikel |
124 |
Viral diagnostics
|
|
|
1999 |
5 |
S3 |
p. 205-210 6 p. |
artikel |
125 |
Viral diseases
|
|
|
1999 |
5 |
S3 |
p. 210-218 9 p. |
artikel |
126 |
Viral infections (except HIV)
|
|
|
1999 |
5 |
S3 |
p. 77-80 4 p. |
artikel |